Table 2.

Patient characteristics in population of patients who experienced fractures

Patient	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Age	57	73	68	64	69	87	75	76	65	62	67	63	86	66	55
Site of PIF	Cervical cancer	Cervical cancer	Cervical cancer	Cervical cancer	Cervical cancer	Cervical cancer	Endometrial cancer	Endometrial cancer	Endometrial cancer	Endometrial cancer	Anal canal	Anal canal	Anal canal	Anal canal	Anal canal
Histology of the primary tumour	SCC	SCC	SCC	SCC	SCC	SCC	ADK	ADK	ADK	ADK	SCC	SCC	SCC	SCC	SCC
Stage/FIGO/	IIIb	IV	IIb	III	IIb	II	II	IIIc	Ib	II	II	IIIa	IIIa	IIIb	IIIa
Latency period (months)	34	66	11	3	3	7	11	13	15	16	10	36	46	6	8
RT treatment modalities volume dose (Gy)	IMRT pelvis + LA : 45 Gy boost to T and pelvic LN 20 Gy (TD 65 Gy)	IMRT pelvis + LA: 45 Gy	IMRT pelvis + LA : 45 pelvic LN :57.6 brachytherapy 25 Gy PDR	IMRT pelvis 45 LN:59 T: 65 Gy	Pre-operative PDR brachytherapy 60 Gy IMRT pelvis 45 N 50 Gy	IMRT pelvis 45 T 65 Gy	IMRT pelvis 45 + curie 10 Gy HDR	IMRT pelvis 45 T 50	IMRT pelvis 45 + brachytherapy 10 Gy HDR	IMRT pelvis 45 T 50.4 brachytherapy 15 Gy PDR	IMRT pelvis 45 T 65	IMRT pelvis 45 T 65 LN 51	IMRT pelvis 45 T 65	IMRT pelvis 45 T 65	IMRT pelvis 45 T 65
Maximal dose at the site of the PIF (Gy)	68.4	47.3	58.5	57.1	50.3	58.3	45.5	40.8	45.5	45.2	52.6	48.8	46.4	62.3	65.1

ADK, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; HDR, high dose rate; IMRT, intensity-modulated radiation therapy; LA, lomboaortic; LN, lymph node; PDR, pulse dose rate; PIF, pelvic insufficiency fracture; SCC, squamous-cell carcinoma; T, tumour; TD, total dose.